# Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

> **NCT04608045** · PHASE1 · COMPLETED · sponsor: **CicloMed LLC** · enrollment: 9 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** CPX-POM

## Key facts

- **NCT ID:** NCT04608045
- **Lead sponsor:** CicloMed LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-19
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608045, "Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04608045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*